My ePortfolio Register   

AACR 2014 /
Subset of breast cancer patients found to benefit from neratinib in latest trial

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1879
Rating:

Dr John W. Park - University of California San Francisco, San Francisco, USA

Dr Park talks to ecancertv at the AACR conference about his work with the investigational drug, neratinib.

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for hormone receptor (HR)-negative, HER2-positive primary (non-metastatic) breast cancer patients.

Read the article or watch the press conference for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence